Security record · archived quarter
LENZ
LENZ Therapeutics, Inc. · Healthcare · Biotechnology
5Tracked holders
—Δ holders
1.34MShares held
$23.21MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 0 | 17.94M | $101.96M | +9 | −9 |
| Q1 2026 | 63 | -5 | 16.96M | $155.30M | +10 | −15 |
| Q4 2025 | 68 | +1 | 17.01M | $272.30M | +3 | −2 |
| Q3 2025 | 14 | +1 | 5.86M | $273.11M | +1 | — |
| Q2 2025 | 10 | -1 | 5.40M | $158.18M | — | −1 |
| Q1 2025 | 8 | 0 | 2.39M | $61.53M | +2 | −2 |
| Q4 2024 | 8 | +1 | 2.51M | $72.56M | +1 | — |
| Q3 2024 | 6 | +1 | 1.75M | $41.57M | +2 | −1 |
| Q2 2024 | 5 | — | 1.34M | $23.21M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 864.94K | — | $14.95M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 360.12K | — | $6.23M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 360.12K | — | $6.23M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 60.17K | — | $1.04M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 34.28K | — | $592,632 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 22.55K | — | $389,959 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 143 holders, 33.15M shares, $300.01M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API